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Abstract
Rapid advances in DNA sequencing technology (“next-generation sequencing”) have inspired 
optimism about the future potential of human genomics for “precision medicine.” Meanwhile, 
pathogen genomics is already delivering “precision public health” via more effective foodborne 
illness outbreak investigations, better targeted tuberculosis control, and more timely and granular 
influenza surveillance to inform vaccine strain selection. In this article, we describe how public 
health agencies are rapidly adopting pathogen genomics to improve their effectiveness in almost 
all domains of infectious disease. This momentum is likely to continue, given ongoing 
development in sequencing and sequencing-related technologies.
An important transformation is underway in public health. Next-generation sequencing 
(NGS, also called “high-throughput sequencing”) is reshaping communicable disease 
surveillance, allowing for earlier detection and more precise investigation of outbreaks. NGS 
helps characterize microbes more effectively and offers new insights into their ecology and 
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transmission. The plethora of sequence data provides raw material for research and 
development of new diagnostics and therapeutics.
This article describes how pathogen genomics has been changing public health in the United 
States and globally.
Adapting NGS to Public Health Use
The NGS era began with the commercial release of massively parallel pyrosequencing in 
2005, the first fundamental advance in sequencing technology since the invention of Sanger 
sequencing in the 1970s. 1,2 In the early years, NGS efficiency improved rapidly, with 
sequencing costs falling by as much as 80% year-over-year. 1,3 In public health, these 
developments were both exciting—because of the myriad potential applications, including 
bacterial whole-genome sequencing (WGS)4—and intimidating—because of the barriers: 
implementing NGS would require investment in sequencing equipment as well as high-
performance computing infrastructure to move, store and analyze large volumes of sequence 
data. Equally important was the need to integrate bioinformatics, a discipline new to public 
health.
Public Health England was an early leader in the use of NGS at a national scale, particularly 
for tuberculosis5,6 and bacterial foodborne disease surveillance.7,8 In the United States, CDC 
was a late adopter,9 but is now applying the technology broadly, due largely to the Advanced 
Molecular Detection (AMD) program, a $30 million dollar per year initiative established by 
Congress in 2013 to bring NGS and other innovative laboratory technologies to bear against 
infectious disease threats, first at CDC and then in state and local public health departments 
nationwide.
Applications of Pathogen Genomics
Today, pathogen genomics is part of almost every infectious disease program at CDC.10 
Some applications of NGS that serve specialized purposes, such as reference testing, are in 
use only at CDC, while others drive entire domestic surveillance systems. Below, we provide 
examples to highlight the value of NGS technology for public health (Box).
Bacterial foodborne illness.
In the mid-1990s, U.S. foodborne disease programs first began applying standardized 
molecular subtyping—pulsed-field gel electrophoresis (PFGE)—to bacterial pathogens as 
part of routine surveillance, leading to a fundamental change in how outbreaks were 
identified and investigated. The resulting national network, “PulseNet”, now includes more 
than 80 public health laboratories.11 Before PulseNet, outbreaks were difficult to detect and 
solve unless they were large or very geographically and temporally focused. For example, 
during the 20-year period before PulseNet, only five outbreaks of listeriosis (0.25 per year) 
were solved (i.e., with a food source identified),12 with a mean of 54 cases per outbreak. In 
the 5-year period after PulseNet began, 11 outbreaks were identified (2.2 per year) with a 
median of 5 cases per outbreak.12 Routine use of PFGE had a similar impact on the 
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detection and response to other foodborne bacteria, particularly Salmonella13 and Shiga 
toxin-producing Escherichia coli (STEC).14–16
PulseNet has now transitioned from PFGE to WGS.17,18 Partners in this effort include the 
U.S. Food and Drug Administration, whose GenomeTrakr system19,20 performs WGS of 
food and environmental isolates, the U.S. Department of Agriculture, and the National 
Center for Biotechnology Information (NCBI).
Compared with PFGE, WGS offers a vastly finer resolution: typically, a three- to six-million 
base-pair sequence, in contrast to a gel pattern with ten to twenty bands that reflect changes 
in small parts of the genome. WGS data are inherently digital, standardized, and much less 
dependent on the choice of laboratory protocol. The results reveal evolutionary relationships 
between bacterial isolates, allowing a better understanding of transmission and links 
between cases (Figure 1). WGS can also predict phenotypic characteristics, such as 
virulence, serotype and antimicrobial resistance.15,21–26 Costs for WGS (around $200 to 
$250 per isolate, including consumables, labor, equipment, maintenance and overheads) are 
currently still higher than those for PFGE (around $100 according to the same analysis), 
although the higher costs may be partly or entirely offset by eliminating the need for 
traditional phenotyping assays. In addition, advances in sequencing technology and 
laboratory automation may further reduce WGS costs.
It is too early to know how the transition to WGS will affect U.S. surveillance for more 
common foodborne pathogens, such as Salmonella and STEC; however, early experience 
with Listeria surveillance, which switched to routine WGS in 2014, has been encouraging. 
In the first three years of WGS (September 2013 through August 2016), 18 outbreaks of 
listeriosis were solved (6 per year) with a median of 4 cases per outbreak.27 In the United 
Kingdom, where WGS has been in routine use for STEC since at least 2015, the number of 
clusters detected has doubled.28
Tuberculosis.
Since the 1990s, several DNA fingerprinting technologies have proven useful for subtyping 
Mycobacterium tuberculosis (MTB).29 Identifying closely-related strains allows health 
department investigators to detect clusters of cases that may be linked to recent transmission
—cases requiring more intense investigation and possible intervention.30 WGS offers much 
finer resolution subtyping than older technologies and thus more confidence in the inferred 
relationships among cases. After using WGS selectively for several years, the U.S. 
tuberculosis control program has now scaled up to sequence isolates from all culture-
confirmed cases nationwide. In California, WGS allowed public health workers to refute 
more than half of suspected outbreaks initially identified by conventional genotyping, saving 
time and resources (personal communication, Tambi Shaw, California Department of Public 
Health). Early experience in U.K.,5 Canadian,31,32 and Dutch33 tuberculosis programs has 
also confirmed that WGS supports more effective investigations by more accurately defining 
outbreaks5,31,33, providing insights into transmission dynamics,34 and sometimes suggesting 
the presence of previously unidentified cases or possible “super-spreaders” that should be 
prioritized for isolation and treatment.5,31 WGS may also indicate whether recurrent cases 
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are due to reactivation or reinfection, information useful in evaluating program effectiveness.
35
The ability to prioritize case-investigations may also be of use in the high-incidence, low- 
and middle-income countries which carry the world’s heaviest burden of tuberculosis.36 In 
these countries, however, a different application of NGS—sequencing of MTB directly from 
sputum—could have an even more important role.37 Direct sequencing of MTB from smear-
positive sputum samples is already feasible in research settings38–40 but is too expensive and 
cumbersome for routine clinical and public health use. If it can be made practical and cost-
effective, this approach will enable rapid inference of drug susceptibility, which is already 
quite accurate for most first-line drugs, and will improve as more data become available.37,41 
In addition to supporting prompt treatment with appropriate drugs, NGS will reduce the 
need for routine phenotypic testing, which is complex, slow, and difficult to maintain in 
resource-limited laboratory settings.
In the meantime, an intermediate strategy is already practical in high-income countries: 
WGS directly from early positive cultures, providing information on drug susceptibility 
weeks before the results of traditional tests are available.38 Laboratories in both the New 
York State Department of Health and Public Health England37 have received regulatory 
approval to forego traditional drug-susceptibility testing of isolates predicted by WGS to be 
susceptible to all four first-line drugs—approximately 70–80% of all isolates.37
Another promising strategy is targeted amplicon sequencing of selected mycobacterial genes 
or marker sequences.42 To remain relevant over time, any sequence-based method for 
inferring drug susceptibility must rely on the continuous updating of databases with 
correlated genotypic and phenotypic data.37
Influenza.
The selection of seasonal influenza vaccine candidate strains is a complex, global 
undertaking, involving massive surveillance efforts from dozens of countries and 
contributing organizations. The World Health Organization (WHO) convenes international 
experts twice yearly to review information on circulating influenza strains and, based on that 
information, to recommend components of the Northern and Southern Hemisphere influenza 
vaccines.43 CDC contributes to this process by overseeing characterization of 4,000 to 
10,000 influenza specimens each year.44
The traditional method for characterizing influenza strains begins with viral culture, which is 
increasingly challenging for certain strains, particularly H3N2.45 Two or more passages 
through culture are often required, during which some adaptation of the virus may occur. 
Next, a few viral isolates are selected for phenotyping, which previously included antigenic 
characterization and consensus (Sanger) sequencing of selected genes. These steps are time-
consuming and labor-intensive.
NGS now enables a more efficient “sequence-first” approach, in which original specimens 
are subjected directly to whole-genome reverse-transcriptase PCR, followed by sequencing.
45–47
 These sequence data provide a highly granular view of viral emergence and allow for a 
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more parsimonious selection of viruses for phenotypic characterization, including antigenic 
analysis and susceptibility to antiviral agents. This approach is not only faster but also more 
informative. For example, detailed phylogenetic information on all viral segments provides a 
richer picture of how influenza viruses are diversifying to evade existing immunity, and deep 
sequencing (sequencing many copies of the genome from the same sample) can reveal the 
presence of drug-resistant minor variants not reflected in the consensus sequence. 
Sequencing cannot completely replace traditional phenotyping, but sequencing first, using 
clinical specimens, allows it to be done more selectively.
Influenza NGS data are now routinely reviewed at the biannual WHO consultations and have 
already affected vaccine decision-making in at least two major instances, most recently 
contributing to a change in the A(H3N2) vaccine component to target a newly emerging 
clade.45,48,49 NGS data are also used for forecasting the relative importance of emerging 
strains and risk assessment,50–52 characterizing viruses used in vaccine effectiveness studies,
53
 and informing treatment for patients infected with high pandemic risk viruses such as 
H7N9.54,55
Parasitic diseases.
Diagnosis of many parasitic diseases continues to rely on microscopy, a nineteenth-century 
technology that is operator-dependent and resistant to automation. PCR and other diagnostic 
techniques (e.g., serology) have been developed for many common parasites but require 
separate tests for each suspected pathogen.
CDC’s parasitic diseases laboratories are developing a new type of diagnostic test based on 
the targeted and direct sequencing of eukaryotic housekeeping genes. This approach should 
enable the accurate detection of all known potential parasitic agents present in a blood 
sample with a single test. Early validation data suggest that this novel assay is at least as 
sensitive as standard PCR for parasites found in blood.56 Further validation and development 
is ongoing, with plans to add more targets and to adapt the assay to more complex samples, 
including tissue and stool.
PCR amplification and NGS of specific genes is an effective means of identifying drug-
resistance in malaria parasites.57 Because such testing takes 2–3 days and is still somewhat 
expensive, its use in routine patient care remains limited. For surveillance at the country or 
regional level, however, it is a cost-effective and efficient way to assess drug resistance and 
to target treatment recommendations more precisely. NGS-based protocols may also be 
useful for assessing the intensity of transmission by gauging multiplicity of infection among 
residents in malaria-endemic areas.58
Cyclospora cayetanensis causes outbreaks of foodborne diarrheal disease in the US every 
year. The organism’s limited genotypic variability and its inability to be propagated in the 
laboratory have confounded the development of effective genotyping methods for 
surveillance. CDC has developed a method to extract C. cayetanensis directly from stool and 
used it to produce whole genomes of multiple isolates.59 Several promising genotyping 
targets have been identified and their translation into a functional and discriminatory 
genotyping tool is showing promise.60 The genotyping tool and associated analysis system 
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underwent further testing and validation during 2018’s unusually active summer 
cyclosporiasis season.
Other applications.
NGS is applicable across the spectrum of important pathogens in public health. For 
Legionnaires’ disease, for example, finer subtyping has been useful for investigating and 
responding to outbreaks.61,62 Eventually, insights from NGS into Legionella ecology and 
persistence in water systems could improve prevention.63 For hospital acquired infections, 
NGS is proving to be an invaluable tool for identifying and investigating outbreaks64,65 and 
also for better understanding transmission both at the hospital65 and community64,66 level. 
For HIV, genetic sequence data generated for clinical purposes can be analyzed to identify 
potential clusters for early public-health intervention;67,68 user-friendly tools69 now allow 
state and local health departments to make use of these data. Community-level molecular 
surveillance for hepatitis C clusters has also proven useful.70
Other applications for NGS in public health include tracking the emergence of antimicrobial 
resistance and novel resistant pathogens such as Candida auris,66,71 tracking insecticide 
resistance in mosquito vectors of disease,72,73 monitoring streptococcal pathogens,74,75 
investigating potential clusters of meningitis,76 and many more.
Sequencing to support outbreak response.
An important subset of NGS applications in public health involves outbreak response.77 For 
bacterial foodborne disease, for example, sequencing is central to detecting outbreaks, 
investigating cases, confirming the implicated food and tracing it back to its source. A very 
different example comes from the latter phases of the 2014-’16 Ebola outbreak in Guinea, in 
which sequencing was useful in ascertaining the likely source of infection in “outlier” cases
—those with no known connection to other cases. Each outlier raised troubling questions: 
Did the case represent another introduction from an animal reservoir? Was it attributable to 
sexual transmission? Had a long chain of transmission been missed, suggesting serious gaps 
in surveillance? Each of these would require a different response. Fortunately, in this 
outbreak, sequences from outliers were consistently closely related to those in the known 
outbreak zone, and the response team was able to remain focused on stopping transmission 
there.10,78
In contrast, sequencing Zika virus during its emergence in the Americas was not useful for 
responding to individual cases. However, sequence data were critical for developing 
diagnostics and vaccines, to better understand the evolution of the epidemic,79 and recently 
to support evidence of an undetected outbreak in Cuba.80 Analysis of Ebola virus genomes 
after the West Africa outbreak also provided useful insights into the virus’s spread.81
Where to Go Next?
Six years into the AMD program, NGS is now central to US public health programs for 
monitoring, controlling, and preventing infectious diseases. Progress is currently needed in 
several areas:
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Metagenomics.
Sequencing, particularly bacterial WGS, often requires pure cultures of the organisms, 
which are increasingly difficult to obtain as clinical laboratories expand the use of highly 
multiplexed, syndrome-based, culture-independent diagnostic tests.82,83 Most immediately, 
this trend is adversely affecting enteric disease surveillance as clinical laboratories move 
away from culture.84 One solution may be to bypass culture, sequencing pathogen genomes 
directly from specimens.38,85 Although already feasible for selected organisms in particular 
specimens, the methods are not yet practical for routine use.
Data integration and data science.
In public health settings, laboratory and epidemiologic data are often stored and managed 
separately. Until recently, these data could be brought together for analysis without loss of 
information: laboratory data such as a positive/negative result, a titer, or even a PFGE 
pattern identifier could be imported into an epidemiologic database and analyzed with 
traditional statistical tools. With pathogen genomic data, this is no longer true: these data 
need to be integrated to realize the full value of both.31,86,87
Fortunately, academic research is addressing this challenge,88 producing tools for 
visualizing and analyzing epidemiologic and phylogenetic data together, such as Microreact 
(microreact.org),89 Nextstrain (nextstrain.org)90 or the Interactive Tree of Life (itol.embl.de).
91
 More broadly, the emerging field of data science offers novel approaches for integrating, 
analyzing and visualizing increasingly diverse public health data.20,92
Software to facilitate NGS workflows.
Complex workflows are required to manage the sequencing process, analyze raw sequence 
data, store processed data and integrate it with epidemiologic data, and finally, share 
information securely. In a single academic lab, it’s feasible for a bioinformatician to 
accomplish this, but in a network of public health laboratories, it can be more practical to 
manage much of this centrally. Bioinformatics tools are available to accomplish the basic 
steps of assembling raw sequence data into genomes and “pipelines” using these tools are 
available to automate core processes, such as validating quality, assembling a genome, and 
inferring phenotypes. However, user-friendly tools for managing workflows and integrating 
data are often lacking. In other instances, too many tools exist and it is not clear which ones 
will survive the test of time.
Challenges
Workforce transformation, both among microbiologists and epidemiologists, while perhaps 
the most obvious hurdle, is in some ways the least challenging due to enthusiasm about 
genomics. Even recruiting and retaining bioinformaticians has not been as difficult as 
initially anticipated. Among the first 27 recruits into the CDC/Association of Public Health 
Laboratories Bioinformatics Fellowship, 19 (70.4%) are still working in public health, 
despite a competitive marketplace. Those who stay in public health often cite the 
opportunity to have positive social impact as a key motivator.
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Costs represent a more difficult issue. For now, sequencing is often more expensive than 
traditional subtyping. In addition, to minimize per-sample costs, sequencing technologies 
such as the MiSeq platform (Illumina, San Diego, Calif.) may require batch sizes of 15 
samples or more, which can extend turn-around times beyond the 36 hours needed for the 
sequencing itself. Clearly, during a fast-moving outbreak, such delays are undesirable. 
Single-molecule, long-read sequencing technology, most notably the MinION (Oxford 
Nanopore Technologies, Oxford, UK), already has niche uses within public health because 
of its portability, but also has the potential to reduce batch-size needs and turn-around times.
78
Data Openness
In both academia and public health, pathogen genomics is ushering in a new era in data 
openness. In the United States, local, state and federal agencies are uploading data on 
bacterial foodborne pathogens,20 influenza45 and other pathogens to public databases hosted 
by NCBI (ncbi.nlm.nih.gov/pathogens), making these data available in near real time. These 
groups also contribute to other global databases, such as the Relational TB Sequencing Data 
Platform (“ReSeqTB”, reseqtb.org) and the Global Initiative on Sharing All Influenza Data 
(GISAID, gisaid.org), established to promote international exchange of sequence and other 
data. In addition to enabling secondary uses of data, openness also encourages collaboration 
among public health organizations, academia, and industry. Nevertheless, openness can 
never be complete and unconditional: public health agencies have always been vigilant 
guardians of confidentiality, and pathogen genomic data are released only after careful 
consideration of risks.87,93,94
Conclusion
NGS and bioinformatics are transforming the response to infectious disease outbreaks, 
providing new insights into disease emergence and transmission, expediting pathogen 
characterization, and promoting data sharing (Figure 2). In public health, sequencing is 
already routine in many core domains, including foodborne bacterial pathogens, 
tuberculosis, influenza and antimicrobial resistance. These developments are taking place 
within a rapidly evolving technology landscape: NGS is becoming more automated, 
efficient, and accurate and related technologies, such as systems for highly multiplexed 
DNA amplification, are advancing.
Public health workforce development is central to this process. Microbiologists need a 
strong knowledge base in microbial genomics. Epidemiologists need the skills and tools to 
translate genomic data into public-health action. Both groups need to grasp the basic 
vocabulary of bioinformatics. Public health should strive to attract professionals with 
broadly applicable data-science skills. For anyone considering a career in public health, this 
is an exciting time to jump in.
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Box:
Generalizations about Sequencing in Public Health
Several attributes of next-generation sequencing are driving adoption of the technology 
within public health:
• High resolution subtyping of pathogens
– Examples
♦ Bacterial enteric illness: improves detection of and 
response to outbreaks.
♦ Tuberculosis: allows better targeting of interventions to 
stop transmission.
♦ Legionella: provides new tool to understand the ecology of 
the pathogen in water systems.
♦ Potential agents of bioterrorism: allows for improved 
forensics.
– Caveats: Legacy technologies often need to be continued during a 
transition period, since older subtyping characterizations often can’t 
be reliably predicted from nucleic acid sequence data; PFGE 
patterns, for example, usually cannot be predicted from routine 
whole-genome sequencing.
• Efficient inference of phenotypic traits
– Examples
♦ Serotyping: In US public health labs, influenza viruses are 
now subject to a “sequencing first” approach, in which 
antigenic type and subtype can be inferred from the 
sequence; only a subset of viruses undergo traditional 
typing and subtyping. For pathogens such as E. coli,15,18,24 
Salmonella25,26 or pneumococcus,95 serotype can usually 
be inferred from sequence data, without the need to acquire 
and maintain serum panels.
♦ Antimicrobial resistance: for bacterial pathogens such as 
Salmonella,21,22 Escherichia coli,23 Streptococcus,75,95 
MTB, or gonococcus96 (to name but a few), antimicrobial 
resistance is increasingly inferred from genomic data.
♦ Virulence: known virulence factors, such as the presence or 
absence of Shiga toxin genes in an E. coli strain, can also 
be inferred from genomic data.
– Caveats: There will probably always be a need for traditional 
phenotyping. The ability to predict a phenotype from a genome 
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generally relies on known correlations between the phenotypic 
characteristics and specific genetic sequences. Particularly in rapidly 
evolving species such as influenza, those correlations will need 
constant updating. In addition, the consistency of those correlations 
is variable. The reliability of inferred antimicrobial resistance, for 
example, is highly dependent on the type of antibiotic, the 
mechanism of resistance, and the species of bacteria. This reliability 
should improve over time as more data become available and 
algorithms for predicting phenotype improve. The capability to infer 
phenotype from genotype means that fewer traditional tests will 
need to be done in the future, and that fewer laboratories (i.e., 
reference laboratories) will need to maintain the capacity to perform 
them.
• “Deep sequencing” rather than “consensus sequencing”. Whereas Sanger 
sequencing generally provides a single, “consensus” sequence from a sample, 
NGS typically provides many (often hundreds, thousands or more) “reads” of 
the gene or amplicon.
– Examples
♦ Malaria: In highly endemic areas, infection with multiple 
strains of malaria is common. In such cases, Sanger 
sequencing usually reflects only the most dominant strain 
in the individual and can miss the presence of other strains, 
which may have differing resistance to anti-malarial agents. 
In malaria endemic areas, deep sequencing can also be used 
to quantify the number of strains in an individual, a 
correlate of the intensity of transmission and potentially a 
tool for evaluating the impact of community interventions.
♦ Hepatitis C: Hepatitis C virus mutates rapidly in 
individuals, resulting in a “swarm of quasispecies”. Data on 
the diversity of quasispecies in two individuals provides a 
reliable means of inferring whether they are part of a single 
outbreak.97,98
♦ Influenza: High mutation rates in influenza virus can also 
lead to minor variants with resistance to oseltamivir or 
other antivirals, which could be missed by consensus 
sequencing.
– Caveats: Sequencing errors, which are more common with NGS than 
with Sanger sequencing, can create the illusion of rare variants. 
Careful analysis of potential sequence variants is needed to prevent 
this.
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• More efficient workflows. Characterizing pathogens by means of sequencing 
is sometimes but not universally less laborious and less expensive than 
traditional typing.
– Examples
♦ Escherichia coli: Shiga toxin-producing E coli (STEC) are 
a common cause of foodborne illness. A standard workflow 
for characterizing STEC involves determination of 
serotype, traditionally accomplished by means of a panel of 
antisera to determine O antigen and, if indicated, H antigen, 
as well as detection of Shiga toxin or Shiga toxin genes by, 
for example, PCR. All of these characteristics, as well as 
susceptibility or resistance to several antibiotics, can be 
reliably inferred from whole-genome sequencing.
♦ Influenza virus: The United States is now using a 
“sequence first” approach to influenza virus 
characterization (see text).
• Caveats: Sequencing, for the time being, is often more expensive than 
traditional subtyping alone. For bacterial pathogens, for example, whole-
genome sequencing is typically twice as expensive as PFGE alone. However, 
if PFGE for a particular pathogen needs to be accompanied by traditional 
phenotyping such as serotyping, virulence typing, or antimicrobial resistance 
testing, and those features can be reliably inferred from the genome, then the 
sequencing approach is often less expensive.
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Figure 1: Example of sequencing for outbreak detection and investigation.
An important purpose of infectious disease surveillance is identifying outbreaks for 
investigation and intervention. Discovering patterns in the epidemiologic data—i.e., finding 
common exposures among cases that cluster in time and location—can help distinguish 
outbreaks from the often much larger background of sporadic cases. Molecular subtyping 
has played an increasingly central role in this process by detecting cases with isolates that 
share a common molecular “fingerprint.”
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In this figure, we schematically represent surveillance data for a foodborne pathogen, 
Salmonella enterica serovar Enteritidis, reported from one region of the United States in 
2018; in that year, some states in the region were already sequencing Salmonella isolates in 
real time and others had not yet started. In the three panels, each dot represents a case of 
Salmonella Enteritidis gastroenteritis. Gray dots represent cases that were later determined 
to be “sporadic” (i.e., not linked to outbreaks) and colored dots represent cases that were 
eventually linked to outbreaks. The largest of these outbreaks (red dots) began as two 
distinct clusters of disease associated with restaurants in two different states. Whole-genome 
sequencing (WGS) linked these two clusters together and to several other cases outside the 
region.
The first panel (“Unsorted”), displays cases randomly, without regard to molecular 
subtyping.
The second panel represents a grouping of cases based on results of pulsed-field gel 
electrophoresis (PFGE), a molecular subtyping technology that US public health agencies 
have used since the 1990s. In this example, PFGE was mostly successful at grouping cases 
from the largest (red) outbreak; however, the group includes many cases unrelated to the 
outbreak, complicating the investigation and reducing the likelihood of finding the food 
source.
In the third panel, we show that the finer resolution afforded by whole-genome sequencing 
(WGS) was more effective in segregating the red outbreak cases from others. This gave 
investigators more confidence in the cluster definition and allowed them to focus on cases 
that were more likely part of the same outbreak. In this case, epidemiologic investigation 
identified shell eggs as the likely source, which was quickly confirmed by isolating 
Salmonella Enteritidis from the implicated eggs and confirming that its WGS matched that 
from the outbreak cases.
In addition to the outbreak in red, this panel shows four additional outbreaks. Cases in blue 
were part of a restaurant-associated outbreak linked to chicken in a single state. Two cases 
(green) were linked to live poultry exposure as part of a much larger, multistate, multi-strain 
outbreak that occurred mostly outside the region shown here. The five cases in light pink 
were investigated as an outbreak but no food source was identified. The fifteen cases in light 
orange occurred in a state where real-time WGS had not yet been implemented; their 
isolates were not sequenced until a later date, after the apparent outbreak had ended. This 
figure summarizes relationships identified by WGS using a simplified graph; in practice, 
however, the data would be represented as a phylogenetic tree, which contains additional 
detail that more precisely represents the relationships among sequences.
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Figure 2. 
Typical Pathogen Genomics Workflow. From pathogens (a) collected in the course of disease 
surveillance, genomic DNA (b) or RNA are extracted, shorn into shorter segments, labeled, 
and subjected to next-generation (high-throughput) sequencing (c). The raw data from the 
sequencer are sorted, reassembled and aligned to other genomes for comparison (d). The 
assembled genomes are used for several purposes including determining relatedness (e) and 
predicting phenotypic traits such as virulence, antimicrobial resistance, and serotype (f). 
Increasingly, the data made publicly available in real-time for use by researchers and for the 
development of diagnostics, therapeutics and vaccines (g).
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